期刊文献+

进展期乳腺癌蒽环类新辅助化疗效果的预测因素分析 被引量:7

下载PDF
导出
摘要 目的探讨进展期乳腺癌蒽环类新辅助化疗疗效的预测因素,为乳腺癌的规范化和个体化治疗提供依据。方法回顾性分析181例采用蒽环类新辅助化疗的进展期乳腺癌患者,按新辅助化疗病理完全缓解(PCR)情况分为PCR组与非PCR组,进行多因素logistic回归分析。结果单因素分析显示术后淋巴结转移、ER、PR、HER-2/neu、Topo-Ⅱa和分子分型与蒽环类新辅助化疗PCR有关。多因素分析显示,术后淋巴结转移情况、HER-2和Topo-Ⅱa这3项指标进入logistic回归方程,P值分别为0.002、0.021和0.004。结论术后淋巴结转移情况、HER-2和Topo-Ⅱa是蒽环类化疗疗效的独立预测指标,是临床科学合理地选择蒽环类化疗方案治疗乳腺癌的依据,并可作为评估进展期乳腺癌预后的预测因子。
出处 《广东医学》 CAS CSCD 北大核心 2014年第22期3498-3501,共4页 Guangdong Medical Journal
基金 国家自然科学基金资助项目(编号:81260389) 南昌市科技支撑计划项目(编号:洪科发计字[2010]194号-14)
  • 相关文献

参考文献29

  • 1IWAMOTO T. Clinical application of drug delivery systems in cancer chemotherapy : review of the efficacy and side effects of ap- proved drugs[J]. Biol Pharm Bull, 2013, 36(5) : 715 -718.
  • 2HAMMOND M E, HAYES D F, DOWSETT M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of es- trogen and progesterone receptors in breast cancer [ J ]. J Clin Oncol, 2010, 28(16): 2784-2795.
  • 3KAMIL M, YUSUF N, KHALID I, et al. Association between HER - 2/neu over - expression and clinico - pathologic parameters of breast cancer in northern Malaysia[ J]. Ceylon Med J, 2010, 55(1): 9-13.
  • 4GOLDHIRSCH A, WINER E P, COATES A S, et al. Personali- zing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Thera- py of Early Breast Cancer 2013 [ J ]. Ann Oncol, 2013, 24 ( 9 ) : 2206 - 2223.
  • 5ADES F, ZARDAVAS D, PINTO A C, et al. Cardiotoxicity of systemic agents used in breast cancer[ J ]. Breast, 2014, 23 (4) : 317 - 328.
  • 6RASTOGI P, ANDERSON S J, BEAR H D, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B -18 and B -27 [J]. J Clin Oncol, 2008, 26 (5) : 778 - 785.
  • 7BONNEFOI It, L1TIDRE S, PICCART M, et al. Pathological complete response after neoadjuvant chemotherapy is an independ- ent predictive factor irrespective of simplified breast cancer intrin- sic subtypes: a landmark and two - step approach analyses from the EORTC 10994/BIG 1 -00 phase Ⅲ trial[J]. Ann Oncol, 2014, 25(6) : 1128 -1136.
  • 8FISHER E R, WANG J, BRYANT J, et al. Pathobinlngy of pre - operative chemotherapy: findings from the National Surgical Adju- vant Breast and Bowel (NSABP) protocol B - 18 [ J]. Cancer, 2002, 95(4) : 681 -695.
  • 9SCHNEEWEISS A, KATRETCHKO J, SINN H P, et al. Only grading has independent impact on breast cancer survival after ad- justment for pathological response to preoperative chemotherapy [J]. Anticancer Drugs, 2004, 15(2) : 127 - 135.
  • 10KONG X, MORAN M S, ZHANG N, et al. Meta - analysis con- firms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer pa- tients[J]. Enr J Cancer, 2011,47(14) : 2084 -2090.

同被引文献68

引证文献7

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部